Research Reports
- 12/20/2022
Safety and Tolerability Data From Influenza Study Announced
- 11/16/2022
3Q22 Reported – First Influenza Vaccine Data To Be Presented
- 9/12/2022
Influenza Program Update
- 8/16/2022
2Q Reported With Influenza and COVID-19 Product Updates
- 5/12/2022
Influenza Trial Continues With New Clinical Trials Planned For COVID-19
- 4/13/2022
First Results From Influenza Program Announced
- 2/8/2022
Drugs For COVID-19 Advance As The Pandemic Won’t Go Away
- 11/16/2021
3Q21 Reported With Phase 1 Influenza Trial Expected To Begin
- 8/23/2021
2Q21 Reported With Clinical Milestones For 2021-22
- 7/30/2021
Cocrystal’s CDI-45205 Shows Broad Activity Against All Major COVID-19 Variants
- 7/30/2021
CDI-45205 Shows Broad Activity Against COVID-19 Variants
- 6/28/2021
Cocrystal Announces CC-42334 To Start Clinical Studies in Influenza
